RxDoctor Payments Data

Mehul Desai, MD

Pain Medicine · Washington, DCNPI 1114045341

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $223,867 of the $339,070 with a category attached, or 66.0%. 38 manufacturers reported payments, led by Nalu Medical, Inc. at 54.3% of the total. Reporting peaked in 2023 at $96,080 and has fallen 54.8% since, to $43,403 in 2025.

$339,070in general payments, 2019–2025

Across 737 payments — averaging $460.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nalu Medical, Inc.$184K
  • Medtronic$49K
  • Avanos Medical$39K
  • SPR Therapeutics, Inc$22K
  • The Institute Of Musculoskeletal Science And Education$11K
  • Relievant Medsystems, Inc.$10K
  • plus $24K from 32 others
$1,045,350in research payments, 2019–2025

Across 260 payments — averaging $4020.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • SPR Therapeutics, Inc$489K
  • Nalu Medical, Inc.$255K
  • Avanos Medical$84K
  • Abbott$51K
  • MML US, Inc.$44K
  • Stimwave Technologies Incorporated$43K
  • plus $79K from 6 others
$18,210in ownership & investment interests, 2019–2025

Across 6 payments — averaging $3035.00 each. An ownership or investment interest held by the physician or an immediate family member.

  • SPR Therapeutics, Inc$18K

What the payments were for

  • Consulting fees$223,86766%
  • Speaking & faculty fees$62,14918%
  • Travel & lodging$23,9667%
  • Food & beverage$28,4708%
  • Entertainment$6170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pain medicine providers in District of Columbiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$464,767
Medicare patients
569
Services billed
2,642

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tizanidine Hcl62$814
Oxycodone Hcl21$518
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen19$388
Baclofen18$276
Cephalexin13$203
Gabapentin20$119
Hydromorphone Hcl11$101
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen11$91

Paid to pharmacies, not to this prescriber.

Other pain medicine in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →